Latest Breaking News On - Dihydroergotamine mesylate inhalation powder - Page 1 : comparemela.com

Pulmatrix (PULM) Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Pulmatrix (PULM) Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Margaret wasilewskiTed raadDrug administrationPulmatrix incSingle event studyDihydroergotamine mesylate inhalation powderAcute treatmentChief medical officerChief executive officer

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

/PRNewswire/ Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled.

United statesMargaret wasilewskiTimothy mccarthyTed raadDrug administrationCompany quarterly reports on formPrnewswire pulmatrix incExchange commissionPulmatrix incSingle event studyDihydroergotamine mesylate inhalation powderAcute treatmentChief medical officerChief executive officerAnnual meetingAmerican headache